Table 1.
Summary of baseline characteristics for all patients based on treatment approach for early-stage FL
| WW, n = 85 | RT, n = 171 | Systemic therapy,* n = 60 | Systemic + maintenance rituximab, n = 49 | |||||
|---|---|---|---|---|---|---|---|---|
| n/N | % | n/N | % | n/N | % | n/N | % | |
| Age >60 y | 59/85 | 69.4 | 101/170 | 59.4 | 27/60 | 45.0 | 29/48 | 60.4 |
| Male sex | 49/85 | 57.6 | 96/170 | 56.4 | 33/60 | 55.0 | 31/49 | 63.3 |
| ECOG PS ≥2 | 4/84 | 4.7 | 8/171 | 4.7 | 3/60 | 5.0 | 3/49 | 6.1 |
| B symptoms present | 4/85 | 4.7 | 7/167 | 4.2 | 4/60 | 6.7 | 9/49 | 18.4 |
| LoNoDiam >7 cm | 6/56 | 10.7 | 9/132 | 6.8 | 6/41 | 14.6 | 15/42 | 35.7 |
| No. of nodal sites | ||||||||
| 0 | 11/83 | 13.2 | 23/170 | 13.5 | 4/60 | 6.6 | 2/47 | 4.3 |
| 1 | 42/83 | 50.6 | 111/170 | 65.3 | 31/60 | 51.6 | 16/47 | 34.0 |
| 2 | 26/83 | 31.3 | 32/170 | 18.9 | 21/60 | 35.0 | 22/47 | 46.8 |
| 3 | 4/83 | 4.9 | 4/170 | 2.3 | 2/60 | 3.3 | 5/47 | 10.6 |
| 4 | 0/83 | 0 | 0/170 | 0 | 2/60 | 3.3 | 2/47 | 4.3 |
| Extranodal present | 19/85 | 22.3 | 29/171 | 17.0 | 7/60 | 11.7 | 8/47 | 17.0 |
| Stage II | 36/85 | 42.3 | 46/171 | 26.9 | 29/60 | 48.3 | 33/49 | 67.3 |
| Grade 3A | 11/82 | 13.4 | 26/165 | 15.8 | 13/59 | 22.0 | 6/45 | 13.3 |
| B2M >ULN | 9/49 | 18.3 | 19/68 | 27.9 | 7/41 | 17.1 | 7/28 | 25.0 |
| Hb <12 g/dL | 5/84 | 5.9 | 11/169 | 6.5 | 4/59 | 6.8 | 9/49 | 18.4 |
| LDH >ULN | 13/77 | 16.8 | 24/162 | 14.8 | 8/58 | 13.8 | 13/49 | 26.5 |
| FLIPI score | ||||||||
| Low (0-1) | 66/77 | 85.8 | 137/161 | 85.1 | 51/58 | 87.9 | 34/46 | 73.9 |
| Intermediate (2) | 10/77 | 12.9 | 24/161 | 14.9 | 6/58 | 10.4 | 10/46 | 21.7 |
| High (≥3) | 1/77 | 1.3 | 0/161 | 0 | 1/58 | 1.7 | 2/46 | 4.4 |
B2M, β2 microglobulin; ECOG PS, Eastern Cooperative Oncology Group performance status; Hb, hemoglobin; LDH, lactate dehydrogenase; LoNoDiam, largest nodal diameter; ULN, upper limit of normal.
*
Systemic therapy includes immunochemotherapy and CMT.